BRCA1/2 germline testing in non-mucinous epithelial ovarian carcinoma: changing international practice and implications for service provision

Coakley, Maria; Cleary, Vicki; Power, Nicholas; O’Reilly, Seamus

doi:10.1038/ejhg.2016.138

Cited by 2 publications

(3 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is not surprising as these referral sources may advocate more strongly for patients to attend genetics services as surgical, treatment and management decisions (e.g. risk-reducing surgery, PARP inhibitor eligibility) may likely be based on the genetic results (Coakley et al 2017;Eccles et al 2015;Finch et al 2014;Frey and Pothuri 2017). Additionally, in such urgent situations where time limitations for treatment-based decisions play a role, a shorter appointment waiting time is often specifically arranged for patients, which in turn is consistent with our findings that those who have a shorter appointment waiting time are more likely to attend their cancer genetics appointment.…”

Section: Discussionmentioning

confidence: 99%

“…Furthermore, the influence of germline genetic testing on treatment-based decisions (e.g. poly (ADP-ribose) polymerase (PARP) inhibitors for BRCA1 and BRCA2 mutation carriers), as well as the fact that specialized genetics clinicians are in short supply, has further contributed to the strain on cancer genetics services (Coakley et al 2017;Eccles et al 2015;Finch et al 2014;Frey and Pothuri 2017).…”

Section: Introductionmentioning

confidence: 99%

“…Our findings may determine where modifications can be made to current practice models in order to increase patience attendance and, therefore, better utilize cancer genetics resources to ensure that individuals at increased cancer risk attend these services (Buchanan et al 2016;Heald et al 2016). Access to cancer genetics services at an appropriate time is essential, especially in cases where surgical and treatment decisions are dependent on the genetic test result (Coakley et al 2017;Finch et al 2014;Frey and Pothuri 2017).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Impact of Appointment Waiting Time on Attendance Rates at a Clinical Cancer Genetics Service

Shaw

Metras

Ting

et al. 2018

Journal of Genetic Counseling

View full text Add to dashboard Cite

The increase in demand for clinical cancer genetics services has impacted the ability to provide services timeously. Given limited resources, this often results in extended appointment waiting times. Over the last 3 years, the Cancer Genetics Service at the National Cancer Centre Singapore has continued to experience a steady increase in demand for its service. Nevertheless, significant no-show rates have been reported. This study sought to determine whether an association exists between appointment waiting times and attendance rates. Data was gathered for all participants meeting inclusion criteria. Attendance rates and appointment waiting times were calculated. The relationship between mean waiting times for those who did and did not attend their scheduled appointments was evaluated using Welch's t test and linear regression model. The results showed a significant difference in mean appointment waiting times between patients who did and did not attend (32.66 versus 43.50 days respectively; p < 0.0001). Furthermore, patients who waited for longer than 37 days were significantly less likely to attend. No-show rates increased as the waiting time increased, at a rate of 19.60% per 20 days and 21.40% per 30 days. In conclusion, appointment waiting time is a significant predictor for patient attendance. Strategies to ensure patients receive an appointment within the necessary timeframe at the desired setting are important to ensure that individuals at increased cancer risk attend their appointments in order to manage their cancer risks effectively.

show abstract

Section: Discussionmentioning

confidence: 99%